Added Value of Soluble Tumor Necrosis Factor-alpha Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 Diabetes
Carol Forsblom, John Moran, Valma Harjutsalo, Tony Loughman, Johan Waden, Nina Tolonen, Lena Thorn, Markku Saraheimo, Daniel Gordin, Per-Henrik Groop, Merlin C Thomas
DIABETES CARE | AMER DIABETES ASSOC | Published : 2014
OBJECTIVE: Recent studies have suggested that circulating levels of the tumor necrosis factor-α receptor 1 (sTNFαR1) may be a useful predictor for the risk of end-stage renal disease (ESRD) in patients with diabetes. However, its potential utility as a biomarker has not been formally quantified. RESEARCH DESIGN AND METHODS: Circulating levels of sTNFαR1 were assessed in 429 patients with type 1 diabetes and overt nephropathy from the Finnish Diabetic Nephropathy (FinnDiane) cohort study. Predictors of incident ESRD over a median of 9.4 years of follow-up were determined by Cox regression and Fine-Gray competing risk analyses. The added value of sTNFαR1 was estimated via time-dependent receiv..View full abstract
The FinnDiane Study was supported by grants from the Folkhalsan Research Foundation, the Wilhelm and Else Stockmann Foundation, the Liv och Halsa Foundation, the Academy of Finland, and the Finnish Medical Society (Finska Lakaresallskapet).